Tenders Are Invited For Measles-Mumps-Rubella Vaccines – Framework Contract For The Supply Of Mfr Vaccine 2026 – 2030

Measles-Mumps-Rubella Vaccines – Framework Contract For The Supply Of Mfr Vaccine 2026 – 2030. The Framework Agreement Concerns The Supply Of Mfr Vaccine (Measles, Mumps, Rubella Vaccine) In The Period 2026 – 2030. It Is A Requirement That The Offered Vaccine Has A Marketing Authorization Valid For Denmark At The Time Of Submission Of The Offer, Cf. Section 7, Subsection Of The Medicines Act. 1. Additional Requirements For The Vaccine Appear In The Tender Material. It Is Estimated That The Need For The Purchase Of Mfr Vaccines As A Starting Point Is Approx. 130,000 – 150,000 Doses Annually, I.E. A Total Estimated Amount Of Approx. 520,000 – 600,000 Doses During The Term Of The Framework Agreement. The Purpose Of The Framework Agreement Is To Ensure That Ssi Can Make The Necessary Purchase Of The Covered Vaccines For The Public Vaccination Program In Accordance With The Expected Need For Such Vaccines During The Duration Of The Framework Agreement Of Up To 48 Months. The Purchase Under The Agreement Depends On The Decisions Made For The Public Vaccination Program And On The Vaccination Adherence. A Significant Variation In Estimated Annual Consumption Can Thus Be Expected. Considering This And The Fact That The Total Need For Vaccines Can Vary Considerably, Depending On Which Decisions Are Made For The Public Programme, Ssi Can Buy A Total Of Up To 750,000 Doses (The Maximum Quantity) According To The Framework Agreement During Its Term, See Appendix 2 For More Details.